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Abstract 
As ubiquitous inhabitants of Earth, bacteria represent a diverse resource in the 
search for new natural products. In order for the field of natural products to progress, 
new and exciting sources of biodiversity must be continually accessed. Microbiomes, 
the community of commensal and pathogenic microorganisms that live in and on other 
organisms, present a unique opportunity to access new biological diversity. These 
symbiotic bacteria have proven to be prolific producers of natural products and 
represent relatively untapped resource of new secondary metabolites.  
Photorhabdus asymbiotica, a bacterial symbiont of an entomopathogenic nematode 
is an emerging health concern for humans. It engages in a bi-phasic lifestyle that 
switches between symbiotic and pathogenic phases. Its genome had been previously 
sequenced and our analysis of the secondary metabolite pathways indicated it had the 
genetic machinery necessary to produce multiple natural products. Extensive media 
screening studies were employed to induce the production of the encoded for natural 
products. Two known and one new proteasome inhibitors were isolated from the 
optimized culture conditions. The theory that P. asymbiotica’s lifestyle switch is 
governed in part by environmental cues was explored by injecting the bacterium into 
live crickets. Recovery of the bioactive natural products from the cricket corpus 
supported the belief that the nutrient composition of the insect gut plays a role in the life 
cycle switch of P. asymbiotica.  
The microbiomes of mammals are a rich and diverse source of bacteria. While these 
microbiomes are well studied in terms of populations, little is known about their ability 
to produce natural products. The biosynthetic potential of the microbiome of a feral hog 
xi 
was examined. One isolated organism, identified as a new strain of Brevibacillus 
latersporus, was chosen for further genomic and metabolomic characterization. Thirty 
two biosynthetic gene clusters were identified in the organism’s genome. Three known 
bioactive compounds were isolated along with two new natural products. A portion of 
the known and new natural products were matched up with their biosynthetic gene 
clusters. This work showed that symbiotic bacteria from small mammals are worthy of 
further investigation by natural product investigators.  
Finally, a method was developed to sample, isolate, and screen members of 
microbiome communities for biosynthetically talented and culturable organisms. By 
employing the use of liquid handling robots and specialized instrumentation, an 
efficient method for quickly evaluating organisms for secondary metabolites was 
created. By combining an efficient screening method metabolomic investigations, a 
snap shot of the chemical products generated by microbiome members has been 
achieved. 
1 
 Chapter 1: Bacteria as a Source of Bioactive Natural Products 
1.1 The importance of natural products in modern pharmaceuticals 
For thousands of years, chemical substances from plants, animals and microbes  
have played a substantial role in the treatment of human disease.
1
 These small 
molecules, called natural products or secondary metabolites, have become an  important 
source of novel pharmaceuticals, most notably for the treatment of infections and 
cancer.
2
 While their native biological roles are often unknown,
3
 these substances have 
played a significant role in the modern pharmaceutical industry. Since 1981, 
approximately 50% of all approved small-molecule drugs have been derived from or 
inspired by natural products.
4
 From 1981-2004, more than a third of all drug sales were 
based on natural products or natural product inspired compounds.
5
 Despite their 
prominent role in medicine, modern pharmaceutical companies had begun to shy away 
from natural products, believing the natural products pipeline to be exhausted and 
preferring to use a more synthesis dependent approach.
6
  By 2010, the total number of 
approved small molecules reached its second lowest level in the past 30 years however, 
fully half of those were natural product based.
4
 This lull in molecule approval has come 
at a troubling time in modern medicine, as the number of infections by antimicrobial 
resistance organisms is increasing around the globe.
7
 The increased need for novel 
pharmaceuticals and decreasing molecule approval rate indicates that natural products 
remain an important area of investigation. 
 
2 
1.2 Bacteria as a source of natural products 
Bacteria are an important part of the Earth’s biota; they are ubiquitous and account 
for a greater biomass than both plants and animals.
8
  As such, bacteria represent an 
extensive source of natural products. Unlike plant secondary metabolites, whose use in 
traditional medicines guided researchers towards bioactive compounds, bacterial based 
pharmaceuticals were the result of a more targeted screening approach. 
9
 Early 
application of these screening methods were so efficient that members of all the main 
clinically relevant families of antibiotics were discovered by the conclusion of the 
1950s.
9
 This effort in the early years of microbial natural product isolation research, 
through to the present day, has resulted in pharmaceuticals of many drug classes. These 
pharmaceutical classes include antibiotics, antitumor agents, immunosuppressive 
agents, enzyme inhibitors, insecticides, and antiparasitic agents.
9
 Some common 





 represent examples of early antibiotics. Mitomycin
12
 
is an antitumor agent approved for use by the FDA in 1974.
13
 Tacrolimus, discovered in 
1984
14
 and early usages begun in the early 90s
15








Figure 1. Examples of clinically relevant natural products (producing bacterium in 
parenthesis) 
 
1.3 The biosynthetic machinery of secondary metabolite production 
Bacteria have demonstrated that they are talented producers of natural products. 
Through the use of a few key biosynthetic strategies,
16
 bacteria are able to assemble 
compounds spanning a range of structural classes. There is a wide variety of secondary 
metabolite classes but the vast majority of bacterial secondary metabolites are produced 
by two types of gene clusters, polyketide synthases (PKS) and non-ribosomal peptide 
synthases (NRPS). While they produce structurally different compounds, the logic of 
4 
their mechanistic assembly is very similar. A brief outline of these biosynthetic 
assembly lines follows with examples of these structural classes shown in Figure 2.  
The PKS biosynthetic system, involves large proteins, divided into modules, which 
each preform an enzymatic activity. Not every domain, however, is present in every 
system. Through the addition of simple molecular building blocks, such as malonyl-
CoA and methylmalonly-CoA, the PKS domains create secondary metabolites in a 
process that is very similar to fatty acid biosynthesis.  Both processes involve a 
repetitive decarboxylation Claisen thioester condensation of coenzyme A, which forms 
the anchor of the growing molecular chain.
17
 Additional enzymatic processing produces 
highly functionally-substituted fatty acids.
18
 The enzymatic architecture, molecular 
building blocks and mode of action can be used to divide PKSs into three general types, 
type I, II and III, to produce a heterogenous group of complex compounds.   
NRPSs are large multifunctional enzymes that use proteogenic and/or 
nonproteogenic amino acids as substrates to produce secondary metabolites.
19
 Like 
PKSs, they are divided into modules that perform specific tasks. The three most 
important subunits are the adenylation domain, the peptidyl carrier protein and the 
condensation domain. They are responsible for substrate recognition and activation, the 




While the list of bacterial pharmaceutical examples is extensive, the potential well 
of natural products from bacterial sources has not been tapped dry. There is still a 
wealth of compounds waiting to be isolated. As an example, it is estimated that only 1-




combining conventional culturing methods with novel culturing environments, genomic 
analysis and heterologous expression, natural products from bacterial sources are able to 






Figure 2. Examples of the major structural classes of bacteria produced natural 
products 
 
1.4 Symbiotic bacteria: Uncovering a surprising source of natural products 
Since the machinery necessary to produce secondary metabolites is encoded for in 
an organism’s genome, it follows that compounds with similar scaffolds are produced 
by homologous gene clusters. A phenomenon in natural product discovery is bacteria 
natural products with structural similarity to invertebrate-derived compounds.
23
 The 
structural similarity of natural products from these widely different organisms lead to 




prokaryotic and eukaryotic genomes exhibit distinct architectural differences, 
examining biosynthetic gene clusters identified through metagenomic analysis can help 
determine whether secondary metabolites are produced by bacteria or the animal host.
25
 
Figure 3 shows an example of this work by looking at the similarities between 
compounds of the pederin family of metabolites isolated from a beetle (Paederus sp.) 
and a sponge (Psammocinia sp.). Pederin, originally isolated from a beetle,
26
 is 





  The Piel group illustrated in a series of publications using a 
genetic approach of exploring the biosynthetic gene clusters that the pederin family is 
produced by a symbiotic Pseudomonas species and not the sponge or beetle host.
25, 29
 
Another example of symbiotic bacteria being responsible for previously isolated 
compounds comes from a recently published paper showing bengamide E, an anti-
tumor and immunosuppressant compound, is in actuality produced by an associated 
culturable myxobacteria, Myxococcis virescens.
30
 The work by these groups, and others, 




Figure 3. Examples of structurally related compounds isolated from very different 
sources (in parenthesis). Their biosynthetic origins are bacterial symbionts.  
 
1.5 Mammalian microbiomes: a potential solution to some field specific problems 
Natural products are widely accepted as the future of drug discovery. 
31
 If the field 
of natural products wishes to continue to be successful and move forward, it is essential 
to begin to solve some of the field specific challenges and reduce the bottle necks in the 
drug discovery process. As with any field, there are a number of areas that can be 
improved upon and multiple ways of achieving similar goals. The current state of 
natural products research, and the inherent problems associated with it, can be distilled 
into two broad areas: accessing new biodiversity and addressing the lingering doubts 
8 
from pharmaceutical companies. Mammalian bacterial microbiomes could be one way 
of solving these problems.  
Originally defined by Lederberg as “[the] ecological community of commensal, 
symbiotic and pathogenic microorganisms that literally share our body space”, 
32
 this 
term has expanded to include microbial communities of other organisms.  The 
mammalian microbiome consists of the bacteria and fungi, both symbiotic and 
pathogenic, which live in association with the mammal. They are located throughout the 
animal’s body; for example in the aural, nasal, oral, anal and vaginal cavities. The most 
well studied microbiomes of higher order animals, such as farm animals and humans, 
are the intestinal microbiomes. The gut is home to a rich and extremely diverse 
microbial community that lives and thrives in a symbiotic relationship with their hosts.  
Gaining access to new biodiversity in the form of previously unknown or uncultured 
bacteria is essential to unlocking a new source of novel natural products. Historically, 
access to an untapped resource of biologics has resulted in an outpouring of new 
secondary metabolites. 
33
 Traditionally, sample collection by natural products 
researchers in remote areas is met with a variety of difficulties: multinational treaties on 
biodiversity
34
, and concerns by local governments
6
 complicate the collection process. 
Environmental changes due to seasonal variations or extinction due to natural or 
anthropogenic make return trips to collect additional samples difficult. 
It is estimated that less than 0.1% of Earth’s bacteria has been isolated and 
cultured,
35
 indicating that bacteria is a largely untapped resource in the search for 
natural products. Gaining access to new biodiversity in the form of previously unknown 
9 
and uncultured bacteria could open the doors to a vast new resource of secondary 
metabolites.  
Bacteria participate symbiotic relationships with other bacteria, plants, fungi, 





 Figure 4 shows a sampling of compounds produced by symbiotic 
bacteria. Volicitin, an N-acyl amino acid present in the saliva of caterpillars and 
produced by gut associated bacteria,
37
 elicits a plant to release volatile compounds that 
attract natural predators of the plant.
38
  Swinholide, a cytotoxic compound isolated 
originally from a sponge,
39
 was later shown to originate from associated 
cyanobacteria.
40




There is, however, little information on the microbiota of mammals and their natural 
products.  Vertebrate microbiome members have evolved together over time, often 
persisting for the life of the mammal and are host specific.
42
 However, their total 
community population is fluid, and relative populations can change based on diet or 
environment.  The mammalian microbiome, although thoroughly studied in how it 
relates to health and disease of certain mammals, has not been explored as a source of 
natural products. Exploring the mammalian microbiome can address some of the pitfalls 
of natural product sample collection.  
Finally, in order for natural products drug discovery to reach its full potential, the 
paradigm of the large pharmaceutical industry much change. Record sales and high 
stock holder expectation resulted in an industry culture of “blockbuster drugs”, wherein 




response, pharmaceutical companies have adopted a high throughput screening (HTS) 
method of synthetic compound libraries against specific targets.
21
 While this method is 
quick and efficient, the “hit rate” (defined as compounds that are eventually 
commercialized) is extremely low, <0.001%.
44
 Clearly, although fast and easy to screen 
an extensive amount of compounds, this method is far less effective than the hit rate 
associated with natural product screenings. Only looking at polyketide metabolites, the 
hit rate is 0.3%
44
, a 300% increase.  The challenge, however, is shifting the prevailing 
attitudes of the pharmaceutical industry. Although the nature of industry is to follow the 
path of least resistance to higher profits, academic and small biotechnology companies 
have picked up the bulk of natural products research.
31
 By accessing new and exciting 
biodiversity, and in turn novel natural products, non-industrial labs can provide new 
insights into natural product research. The mammalian microbiome, with its ease of 
sampling and high potential for bioactive natural products, provides a gateway back 
toward industrial screening of secondary metabolites. With an easily accessible and 
reliable source of microorganisms, coupled with efficient screening methods, 










Chapter 2: Hypothesis and chapter overviews 
2.1 Hypothesis 
Bacteria have traditionally been a rich source of natural products. At the core of 
discovering new natural products is the idea that accessing new biodiversity is essential 
for isolating new chemistry. Symbiotic bacteria are a unique source of biodiversity 
and new natural products.  This hypothesis was tested via the following specific aims: 
1. Isolation of new glidobactin derivatives from Photorhabdus asymbiotica, a 
nematode symbiont and entomopathogenic bacteria.  
2. Isolation of a new bacteria strain from a feral hog microbiome, characterization 
of the secondary metabolite clusters and isolation of new natural products. 
3. Development of a screening method for isolated microorganisms from 
mammalian microbiomes.  
 
2.2 Chapter 3. Production of cytotoxic glidobactins/luminmycins by Photorhabdus 
asymbiotica in liquid media and live crickets 
In this project, we looked at Photorhabdus asymbiotica, a unique bacterium that 
engages in a two part life cycle that requires adaption to both a symbiotic and 
pathogenic phases. The genome of P. asymbiotica contains several gene clusters that are 
predicted to be involved in the biosynthesis of unique secondary metabolites. However, 
recent reports on Photorhabdus sp. secondary metabolite production have indicated that 
many of its genes are silent under laboratory conditions. Using a panel of media and 
fermentation conditions, we have successfully achieved the production of a series of 
13 
new and known glidobactin/luminmycin compounds. These compounds were also 
obtained upon infection of live crickets with the bacterium.  
 
2.3 Chapter 4. Genomic and metabolomic characterization of natural product 
biosynthetic diversity in a strain of Brevibacillus laterosporus isolated from a feral 
hog 
In this project, a bacterium was isolated from a wild hog. Genomic analysis 
indicated that the organism was a new strain of Brevibacillus latersporus. From this 
organism basiliskamides A and B, known antifungal compounds, were isolated. New 
and known indole-pyrazine derivatives were isolated along with a new hybrid peptide. 
The structure of peptide was determined using NMR, MS/MS and x-ray 
crystallography. Finally, the isolated compounds were matched with their biosynthetic 
gene clusters.   
 
2.4 Chapter 5. Development of an efficient and robust screening method for the 
detection of biosynthetically talented organisms from mammalian microbiome 
This chapter focuses on the method development of collecting and purifying 
organisms from the mammalian biome and the development of a screening protocol for 
the identification of biosynthetically talent organisms. We developed a standard 
operating procedure for collecting samples from the mouth, ear, nasal, vaginal, and anal 
cavities as well as the small and large intestines of recently deceased small mammals 
native to central Oklahoma. These samples were purified to obtained pure cultures of 
each organism. Each bacterium was then grown in three different media types, 
14 
representing one nutrient rich environment and two minimal nutrient environments. 
These cultures were extracted using an automated liquid handling system and analyzed 
by LC-ESI-MS. The total ion trace was analyzed for each extract to identify prolific 
metabolite producers. The bacteria were regrown, extracted and each extract tested for 
antimicrobial and antitumor activity.  
  
15 
Chapter 3. Production of cytotoxic glidobactin/luminmycins in liquid 
media and live crickets 
Adapted from a previously published article in the Journal of Natural Products.
45
 
3.1 Introduction and discussion 
Photorhabdus spp. live in association with a variety of soil-dwelling 
entomopathogenic Heterorhabditis nematodes.
46
  After the nematode infects an insect, 
the bacterial symbiont is released, which kills the insect and provides the nematode a 
rich food source for growth and reproduction.
47
  Once the insect food resources are 
exhausted, the bacteria recolonize the nematode, which reemerges from the insect 
carcass to begin its search for new prey .
46
  These distinct environments, the nematode 
gut and the insect hemolymph, induce the differentiation of Photorhabdus spp. into 
what has been described as two phase variants. 
48
  Phase I (the pathogenic phase) occurs 
in the insect hemolymph and is characterized by the production of a variety of 
proteases, lipases and small molecules.  Phase II (mutualistic phase) occurs in the 
nematode gut and is categorized by a general lack of production of most phase I 




Figure 5. Photorhabdus sp. and nematode life cycle. Phase I stages are indicated by 
blue boxes, phase II by red.  
 
Among the many described Photorhabdus spp., Photorhabdus asymbiotica has 
received less attention from chemists and biologists compared to its better known sister 
species Photorhabdus luminescens and Photorhabdus temperata, as well as closely 
related species in the genus Xenorhabdus.
48
 While it is believed that P. asymbiotica 
engages in a life cycle similar to other Photorhabdus and Xenorhabdus, it is apparent 
that P. asymbiotica has an additional confirmed role as a human pathogen.
51,52
  It has 
been reported that the genome of P. asymbiotica, contains a large number of virulence 
loci and secondary metabolite biosynthetic gene clusters.
53
  The combination of an 






















makes P. asymbiotica an attractive organism to investigate due to its ecological impact 
and human health concerns. 
The genome of P. asymbiotica ATCC43949 has been previously sequenced and 
annotated
54
.  Our reexamination of the genome using the secondary-metabolite gene-
cluster search tool antiSMASH
55
 revealed 19 biosynthetic gene clusters (Table 1), 
which included a group of genes that was decidedly similar to the gene cluster 
attributable to glidobactin production 
56
 (Supporting Information, Figure S1).  A recent 
publication had supported the hypothesis that a closely related Photorhabdus sp. was 
capable of producing glidobactin-like compounds.
57
  Moreover, the same group recently 
verified the presence of a glidobactin gene cluster in P. luminescens via heterologous 
expression in Escherichia coli because this gene cluster was considered to be a “silent” 
biosynthetic pathway when the bacterium was cultured in the laboratory.
58
  Knowing 
that the glidobactins are potent proteasome inhibitors
59
, we used a combination of LC-
MS and bioassay analysis to test for the presence of these compounds.   
However, our initial tests with tryptic soy broth (TSB), a medium in which P. 
asymbiotica grows remarkably well, resulted in no LC-MS evidence for glidobactins 
and produced extracts that tested negative for cytotoxicity.  Expanding on the basic TSB 
recipe, a variety of supplements and changes in the medium formulation were tested 
including: altering the amount of dextrose and peptone in the medium; the addition of 
soil extract, ground invertebrates, nematodes and sterile blood; and alternative carbon 
sources (sucrose, glucose and ribose). However, the ethyl acetate extracts of these 
cultures also proved negative for glidobactins and cytotoxicity.  Consequently, several 
other media formulations were tested including Luria broth, potato dextrose broth, and a 
18 
defined medium used for the induction of secondary metabolites in Streptomyces.
60
  In 
each case, the ethyl acetate extracts generated for cultures grown in these media 
demonstrated cytotoxicity.  In addition, the culture prepared in the defined medium 
exhibited a golden-red hue that was quite distinctive from the colors of the all the 
cultures (pale yellow to cream colored) prepared using other media formulations.  
Analysis of the culture grown in defined medium by LC-MS led to the observation of 
several new peaks (Figure 6), including four substances that were indicative of 
glidobactins (based on their mass spectrometric and UV spectroscopic data). Note the 
appearance of glidobactin/luminmycin peaks appearing between 8-9 minutes (indicated 
by a box) in the defined medium and their absence in TSB.  Refer to Figure 2 for an 
expansion of this region showing the retention times for each glidobactin/luminmycin 
metabolite.  Subsequent bioassay-guided isolation led to purification and dereplication 
of two known compounds, glidobactin A (1)
61
 and luminmycin A( 2).
58
 In addition, two 
presumably new (based on mass spectrometric analysis) glidobactin/luminmycin 
derivatives were also purified resulting in the chemical characterization of a new 
glidobactin analogue, luminmycin D (3).  Unfortunately the other new metabolite 




Figure 6. LC-MS traces (254 nm) of P. asymbiotica in TSB (red, top trace) and defined 
medium (black, lower trace).   
 
Compound 3 was obtained as a white solid.  High resolution electrospray 
ionization mass spectrometry (HRESIMS) analysis provided a [M+H]
+
 peak at m/z 
519.3543, which indicated that the metabolite possessed the molecular formula 




C NMR data were similar to the data collected for 2 with the 
majority of the carbon and proton chemical shifts throughout the 12-membered 
macrocycle and much of the polyketide tail remaining the same.  However, integration 
of the 
1
H NMR spectrum revealed a new methyl signal that was not present in 2.  In 
addition, the existing H-11'' methyl protons were shifted downfield from 1.25 ppm to 
20 
1.50 ppm, while the 
13
C NMR signal of its associated carbon atom was shifted from 
22.1 ppm to 27.0 ppm.  Inspection of the 2D NMR data for 3 helped unambiguously 
determine that the new methyl group was part of a terminal isopropyl unit.  Since the 
specific rotation data for 1 and 2 were identical to those values previously
58, 62
, and we 
presume that compound 3 shares the same biogenic origins, the absolute configurations 
is assumed to be the same as 2. Double bond configurations were confirmed by 
coupling constants. Metabolite 3 has been given the trivial name luminmycin D. 
Structures are shown in Figure 6, NMR data of luminmycin D (3) in table 1.  
 
Figure 7. Structures of isolated compounds, glidobactin A (1), luminmycin A (2), and 










C NMR data. (500 Mhz, DMSO-d6, 25
 o
C) for luminmycin D (3) 
 
Luminmycin D (3) 
Position δC, type
a
 δH (J in Hz) 
2 166.5, CH  
3 118.2, CH 6.23, m 
4 146.4, CH 6.78, dd (15.4,4.6) 
5 45.3, CH 4.41, m 
7 171.0, C  
8 51.1, CH 4.51, m 
9 29.5, CH2 2.07, m 
10 29.4, CH2 1.69, m 
11 29.5, CH2 1.44, m 
12a 37.7, CH2 3.20, m 
12b  2.94,m  
13 18.0, CH3 1.20, d (7.0) 
1' 169.3, C  
2' 57.9, CH 4.32, dd (8.8,3.9) 
4' 66.2, CH 3.99, m 
5' 19.4, CH 1.02, d (6.4) 
1'' 165.9, C  
2'' 122.7, CH 6.17, m 
3'' 139.4, CH 7.00, dd (15.2, 
11.2) 
4'' 128.3, CH 6.17, dd (15.2) 
5'' 141.6, CH 6.09, m 
6'' 31.9, CH2 2.13, q (7.0,7.0,7.0) 
7'' 28.1, CH2 1.37, m 
8'' 28.6, CH2 1.28-1.25, m 
9'' 28.6, CH2 1.28-1.25, m 
10'' 31.0, CH2 1.28-1.25, m 
11'' 27.8, CH 1.5, m 
12'' 23.0, CH3 0.85, d (6.8) 
13'' 23.0, CH3 0.85, d (6.8) 
NH (1)  7.34, dd (6.6) 
NH (6)  8.45, d (7.8) 
NH (14)  7.62, d (7.8) 
NH (3')  8.01, d (8.8) 




The distinct lifecycle variations experienced by P. asymbiotica during its 
symbiotic and pathogenic periods indicates that tight regulation of secondary metabolite 
production must be essential to the bacterium and its host nematode’s survival.
48
  Our 
observations pertaining to the marked variation in the P. asymbiotica metabolome in 
different media types appear to be consistent with the idea that the bacterium requires 
specific environmental cues to induce secondary metabolite production.  Paralleling our 
studies, a recent report from the Müller group had asserted that the biosynthetic genes 
for glidobactins/luminmycins in P. luminescens were “silent,” which led the authors to 
pursue a heterologous expression-based approach for their production.
58
  The challenges 
of producing Photorhabdus metabolites highlighted in this report, coupled with our 
successful production of glidobactins/luminmycins under liquid-state fermentation 
conditions, led us to propose that an insect might provide an appropriate trigger for 
inducing the production of metabolites by P. asymbiotica.   Accordingly, P. asymbiotica 
cells were grown in a non-glidobactin/luminmycin-inducing TSB medium and injected 
into live crickets.  After 24 hours post-inoculation, we observed that all of the P. 
asymbiotica-infected crickets were dead.  The insect carcasses were ground and 
extracted with ethyl acetate.  Examination of the extracts by LC-MS confirmed that all 
four of the glidobactin/luminmycin metabolites produced by P. asymbiotica in the 
defined medium were also present in the cricket corpus (Figure 8). These data further 
reinforce the theory that insects can provide the requisite environment for stimulating 





Figure 8. LCMS single ion trace profiles of various extracts. m/z 521 (glidobactin A) in 
red, m/z 519 (luminmycin D and unknown derivative) in black and m/z 505 
(luminmycin A) in blue. (A) defined media (C) PBS injected cricket blank (E) crickets 
inoculated with P. asymbiotica. (B) (D) and (F) zoomed in to glidobactin/luminmycin 




Metabolites 1-3 were evaluated for toxicity against human pancreatic cancer 
cells to assess their relative potencies (Figure 9 A).  Compounds 1 and 2 exhibited 
similar activity profiles, although 1 was more potent with an IC50 value of 6.99 nM 
(4.35-11.2 95% confidence interval) compared to an IC50 value 17.9 nM (11.4-28.2 
95% confidence interval) for 2.  In contrast, compound 3 was surprisingly much less 
active with an IC50 value of 105 nM (65.9-166 95% confidence interval).  The 
compounds exhibited relatively less toxicity against mouse fibroblasts (Supplemental, 
Figure 9). Since 1 is known to inhibit the proteasomes,
59
 all of the compounds were 
analyzed in a proteasome inhibition assay (Figure 9B).  The results of these experiments 
showed a similar pattern of inhibition compared to the cancer cell cytotoxicity tests with 
1 being slightly more active than 2 and much more active than 3 (IC50 values of 68.6, 
87.6, and 375 nM,  and 95% confidence intervals of 24.2-194, 58.5-131, and 322-437, 
respectively) 
 
Figure 9. In vitro cytoxicity (panel A) and proteasome inhibition (panel B) of 1, 2, and 
3 in MIA-PaCa-2. The data are shown as an average of triplicates with error bars 





3.2.1 General Experimental 
UV data were collected on a Hewlett Packard 8452A diode array 
spectrophotometer. IR data were collected on a Shimadzu IRAffinity FTIR.  Optical 
rotation data was determined on an AutopolIII automatic polarimeter.  NMR data were 
collected on  Varian VNMR 400 MHz NMR and Varian 500 MHz instruments.  
Accurate mass data were collected on an Agilent 6538 HRESI QTOF MS coupled with 
an Agilent 1290 HPLC.  Metabolite profiles were obtained on a Shimadzu LCMS 2020 
system (ESI quadrupole) coupled to a photodiode array detector.  LC-MS samples were 
separated using a Phenomenex Kintex column (2.6 µm C18 column, 100 Å, 75 x 3.0 
mm).  
3.2.2 Microorganisms and culture conditions 
Photorhabdus asymbiotica ATCC 43949 was purchased from ATCC (originally 
deposited as Xenorhabdus luminescens).  For the media panel tests, starter cultures of 
the bacterium were prepared in TSB at room temperature on a rotary shaker at 120 rpm 
for 12 h.  Flasks (1 L Erlenmeyer) containing 300 mL of autoclaved medium (refer to 
Supplemental Information for a list of the media tested and their formulations) were 
seeded with 1 mL of inoculum and allowed to grow for 1 week at 25 ºC on a rotary 
shaker at 120 rpm.  For the scale up metabolite production, a starter culture of the 
bacterium was prepared in TSB at room temperature on a rotary shaker at 120 rpm.  





: KH2PO4 (2.0), NH4Cl (1.5), MgSO4
.
7H2O (0.5), glycerol 








6H2O (0.01), CaCO3 (0.25), p-
aminobenzoate (0.001).  No pH adjustments were performed. The culture was stirred at 
20 rpm at 25 ºC for 1 week.   
 
3.2.3 Extraction and isolation 
A bioactivity guided fractionation procedure was followed.  The scale-up culture 
was removed from the bioreactor and extracted three times with ethyl acetate in a 1:1 
(vol.:vol.).  The organic layers were removed, combined and dried under reduced 
pressure on a rotary evaporator.  The reduced crude extract (3.46g) was absorbed onto 
silica and subjected to fractionation by flash chromatography using a hexane-CH2Cl2-
MeOH gradient.  The bioactive fractions (340 mg) were further fractionated by C18 
HPLC.  A MeOH-H20 gradient (20% for 5 minutes, 20-100% over 50 minutes, 100% 
for 10 minutes) at flow rate of 10 mL/min was used to elute the glidobactin/luminmycin 
metabolites .  This procedure provided an active fraction that was further purified by 
reverse phase semi-preparative HPLC (60% isocratic MeCN) to provide 1 (3.08 mg), 2 
(2.6 mg), and 3 (0.6 mg). 
Luminmycin D (3): white solid; ; [α]D (c 0.06, MeOH)  -14.5;  UV(MeOH) λmax 256nm 






C NMR, see Table 1; HRESIMS 
[M+H]
+
 519.3543 (calcd for C28H46N4O5, 519.3541). 
 
3.2.3 Productin of glidobactins and luminmycins in an insect host 
Live crickets (Acheta domestica) were purchased from Timberline Fisheries through 




  The P. asymbiotica inoculum was grown in a non-glidobactin 
inducing TSB medium.  Bacteria were obtained by centrifugation (8000 ×g), washed 
with PBS, and diluted to a standardized concentration so that we could deliver 10
8
 cells 
in a 2 µL injection.
64
  Crickets were briefly chilled on ice until they appeared lethargic 
and were immediately injected between the third and fourth abdominal segments with 
P. asymbiotica.  Control crickets were injected with sterile PBS.  The treated crickets 
were given access to water and food (corn meal) and left at 25 ºC in the light.  After 24 
h, crickets were flash frozen in liquid nitrogen, crushed with a mortar and pestle, and 
extracted with EtOAc.  The EtOAc was dried under vacuum and resuspended in 9:1 
MeOH-H2O at a concentration of 10 mg/mL for LC-MS analysis. 
 
3.2.4 Cell cytotoxicity assays 
Mammalian cell cytotoxicity assays were performed on cancer cells (MIA PaCa-2) 
and mouse fibroblast cells (NIH/3T3) by adding 2,000 cells per well into 96-well plates 
and the cells were allowed to attach overnight at 37 
o
C in a humidified incubator (5% 
CO2 atmosphere).  Test compounds were diluted in DMSO and added to the wells so 
that the final concentration of DMSO per well did not exceed 1% by volume.  The 





3.2.5 20S proteasome inhibition assay 
The proteasome assay was performed using a colorometric commercial kit 
purchased from Cayman Chemical (item number 10008041).  Briefly, cells were seeded 
28 
at a density of 50,000 cells/well and incubated overnight at 37 
o
C.  Cells are treated with 
compounds for 90 minutes, the plate centrifuged, assay buffers were added, and the 
results read by a plate reader for fluorescent intensity (360 nm and 480 nm excitation 
and emission wavelengths, respectively). The assays were performed cancer cells (MIA 
PaCa-2) and mouse fibroblast cells (NIH/3T3). 
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Chapter 4. Genomic and Metabolomic Insights into the Natural 
Product Biosynthetic Diversity of a Feral Hog Associated Brevibacillus 
laterosporus Strain 
4.1 Introduction 
For decades, nature has served as a valuable source of bioactive compounds 
with many natural products (secondary metabolites) having entered into clinical use 
4
.  
One of the primary reasons the supply of new and inspiring secondary metabolites has 
continued after such a long period of intense research is linked to the tremendous 
biological diversity of organisms from which these compounds are obtained 
4
. Bioactive 
substances with unique chemical features have been discovered from plants, microbes, 
and animals originating from terrestrial and marine environments.  In order to sustain 
the rich pipeline of new chemical entities from nature sources, researchers need to 
maintain a dedicated focus on investigating new biological resources 
33
. 
Initial efforts to characterize animal microbiomes, especially those from 
vertebrate hosts, has uncovered a virtually untapped source of bacterial and archaeal 
diversity.  These microorganisms fulfill a range of critical functions through their 
participation in commensal, symbiotic and pathogenic relationships with the animal 
hosts 
32
.  The spectrum of habitats afforded by a body’s many distinct 
microenvironments substantially increases the number of microbial species that can 
inhabit a single animal.  Bacteria associated with other microbes, plants, nematodes, 
insects and sponges produce an intriguing variety of secondary metabolites 
36
.  In 
contrast, relatively little is known about the natural products generated by the microbial 
symbionts of mammalian hosts.  Larger mammals, such as humans, have a diverse 
30 
microbial population with some members capable of producing bioactive small 
molecules 
66









, and anti-tumor 
71
 properties 
demonstrate the biosynthetic potential of mammalian microbiome members.  It is 
reasonably expected that the unexplored bacterial symbionts of smaller mammals will 
harbor a comparable assortment of biosynthetic gene clusters encoding for secondary 
metabolite production and that these compounds will exhibit a correspondingly wide 
range of promising biological activities. 
In this report, we describe the use of an opportunistic sampling method to access 
secondary metabolites produced by a bacterium derived from a mammalian host.  This 
work describes a new strain of Brevibacillus laterosporus acquired from the ear canal of 
a feral hog originating from southwestern Oklahoma, USA.  The natural product 
biosynthetic potential of the bacterial isolate was revealed using a combination of 
bioassays, LC-MS, and genomic sequencing data.  These efforts provided several 
compounds including a new and unusual peptidic metabolite auriporcine (6), a new 
pyrazine auripyrzine (5), and the previously described antifungal metabolites 
basiliskamides A and B (1 and 2, respectively).  Our research highlights how the 
integrated application of metagenomic and metabolomic approaches offers exciting 
opportunities for mining mammalian microbiomes for new natural products. 
 
4.2 Results and Discussions 
The oral cavity, ear canal, and nasal cavity of a feral hog taken by a hunter in 
southwestern Oklahoma were swabbed for microbial inhabitants within 24 h of being 
31 
bagged.  The samples were spread onto agar media and microbes purified by 
subculturing until bacterial isolates exhibited stable, uniform morphologies.  The 
collection of isolates was transferred to fresh media and agar overlays seeded with 
Staphylococcus aureus were applied.  Several isolates produced clear zones with no S. 
aurerues growth (Figure 10).  One of the bioactive isolates derived from a swab sample 
taken from of the hog’s ear (PE36) was selected for further investigation. 
 
 
Figure 10. Overlay experiment of organisms isolated from a wild hog ear. Isolate PE36 
indicated by an arrow 
 
Genomic analysis of the isolate yielded a total of 16.75 million reads or 2.49 
Gbp with 99.8 percent of reads passing quality filtering (>Q30 across a sliding window 
of 50bp).  A total of 63 scaffolds with a genome size of 5.14 Mbp were obtained upon 
32 
assembly.  These scaffolds had an N50 of 155.81 Kbp and a maximal scaffold length of 
457.91 Kbp producing a near-complete genome assembly (489-fold coverage).  After 
annotation, 4791 coding sequences were split between 430 subsystems along with 100 
RNAs.  The complete 16S small subunit rRNA sequence was used to identify isolate 
PE36 as a member of the family Paenibacillaceae and the genus Brevibacillus (Figure 
11A).  A sequence based comparison of the PE36 genome and those of related 
sequenced strains (i.e., Brevibacillus laterosporus strains LMG15441, GI-9, and DSM 
25, as well as Brevibacillus phR) warranted the designation of PE36 as a separate strain 
of Brevibacillus laterosporus (Figure 11B).  The new Brevibacillus laterosporus strain 
PE36 genome was submitted to the secondary metabolite analysis pipeline antiSMASH 
72
 revealing 32 putative biosynthetic gene clusters.  These included 11 nonribosomal 
peptide synthase (NRPS) clusters, two polyketide synthase (PKS) clusters, and four 





Figure 11. Phylogeny of Brevibacillus laterosporous strain PE36 and close relatives 
depicted by A) maximum likelihood of 16S rRNA gene sequences and B) a consensus 
network based whole genome comparisons.  Bootstrap values >70% are listed for nodes 
in the maximum likelihood tree, with the scale bar representing 0.05 substitutions per 
position. Branch lengths for the genome consensus network are proportional to the 










Table 2. Biosynthetic gene clusters in PE36 identified by antiSMASH analysis. NRPS= 
nonribosomal peptide synthase, PKS = polyketide synthase, T1 = type I, T2 = type II, 
T3 = type III 






6 Putative biosynthetic gene cluster 
7 Putative biosynthetic gene cluster 
8 Putative biosynthetic gene cluster 
9 Putative biosynthetic gene cluster 
10 Siderophore 
11 Bacteriocin/T2PKS/NRSP/trans-ATPKS 







19 Putative biosynthetic gene cluster 
20 Putative biosynthetic gene cluster 









30 Putative biosynthetic gene cluster 
31 Phosphonate 





 Metabolites produced by strain PE36 were isolated and characterized from 
scale-up cultures for structure characterization.  Silica flash chromatography, C18 VLC, 
and preparative and semipreparative C18 RP-HPLC were used to purify the metabolites 
(Figure 3) that were responsible for the extract’s biological activities.  One of the active 
fractions was determined to contain basiliskamides A (4) and B (5) 
73
 the structures of 
which were confirmed by ESIMS, UV and 
1




C-HSQC.  The 
basiliskamides exhibit potent antifungal activities and modest antibacterial properties 
74
. 
These compounds had been previously reported from a sample taken from a bacterium 
associated with a tubeworm collected in Papua New Guinea 
73
.  Another active 
(antibacterial) fraction contained 12-methyltetradecanoic acid (6), which was 






Figure 12. Isolated compounds.  
 
To further access the chemical diversity of the PE36 metabolome, two additional 
fractions were selected for chemical analysis.  LC-MS profiling of the first fraction 
revealed the presence of two compounds possessing similar UV adsorption spectra (λmax 
~220).  One of the compounds was identified as 2,5-bis(3-indolylmethyl)pyrazine (7), 
whereas the second compound is reported here for the first time as a natural product.  
HRESIMS analysis of 5 yielded a molecular ion at m/z 222.1039 [M-H]
-
, which 




C NMR data for 8 were 
remarkably similar to those obtained for 7 (Table 3).  Analysis of the 
1
H NMR data 
revealed a broad exchangeable singlet at δH 10.9, two downfield singlets at δH 8.32 and 
8.36, five aromatic protons (δH 7.22 – 6.94), a singlet integrating for two hydrogens at 
37 
δH 4.17, and a methyl singlet at δH 2.45.  These features could be accounted for if one of 
the two indoles attached to the pyrazine in 4 was replaced by a methyl group in 
compound 5.  The proposed structural change was subsequently confirmed by 2D NMR 
to give the structure of auripyrazine (5). 
 






H (J in Hz) 
   
2 123.7, CH 7.22, m 
3 111.1, C - 
4 125.7, C - 
5 136.1, C - 
6 111.2, CH 7.33, d (8.2) 
7 119.0, CH 6.94, m 
8 119.0, CH 7.48, m 
9 121.5, CH 7.06, m 
10 31.3, CH2 4.17, s 
11 155.4, C - 
12-N - - 
13 142.3, CH 8.32, s 
14 152.3, C - 
15-N - - 
16 141.6, CH 8.35, s 
17 21.8, CH3 2.45, s 
1-NH - 10.92, brs 
 
HRESIMS analysis of 9 provided a molecular ion with m/z 799.5330 [M+H], 
which indicated that the compound had a molecular formula of C43H70N6O8.  An initial 
inspection of the 1H NMR data revealed that 9 was likely peptidic in nature with signals 
characteristic of amide doublet protons, as well as amino-acid α-hydrogen spins.  
Further inspection of the 1D and 2D NMR data revealed the occurrence of many more 
signals than could be accounted for by the proposed molecular formula; however, 
additional attempts at purification of the compound by analytical HPLC proved futile.  
38 
We also observed by 
1
H NMR that the relative distribution of these spins was not 
appreciably altered by switching to different solvent systems (DMSO-d6, acetone- d6, 
CDCl3, MeOH-d4, pyridine-d5) or upon changes to the NMR probe temperature.  
Therefore, we conjectured that 9 might exist in two dominant conformational states that 
were relatively insensitive to the influence of the surrounding solvent. 












H NOESY data 
provided evidence for several discrete spin systems attributable to two prolines and 
three leucines that were linked to form a Pro-Leu-Pro-Leu-Leu peptidic fragment.  




C-gHMBC leading to the 
generation of a six carbon fragment in which two of the carbon atoms were attached to 
oxygen atoms (δC 172.0 and 72.5, amide carbonyl and a hydroxyl-group-bearing 





data helped linked this fragment to the peptide portion of the new metabolite 
(supplemental Figure 1).  The placement of this six carbon fragment at the N-terminus 




N HSQC experiment from which we 
found no evidence for primary amide hydrogens.  The remaining carbon atoms in 9 
were determined to comprise a phenylalaniol residue (phenylalaninol – Pho) at the C-
terminus of the peptide (supplemental Figure 1).  The reduction of the phenylalanine 
carboxyl group to a primary alcohol was confirmed by the presence of a new carbon 
chemical shift at δC 62.4 for the atom bearing the primary alcohol.  A series of MS
n
 
experiments (Table 5) were performed to provide additional substantiation for the 
proposed planar structure of compound 9.  A majority of the fragment ions exhibited a 
loss of water and/or putative intramolecular cyclization as reported for similar structures 
39 
75
.  Several of the fragments were generated through cleavage of the amide bonds, thus 
confirming the proposed sequence of amino acid residues in 9. The assigned NMR 





Table 4. NMR data for 9, showing the data for the different conformations 
  










MHP 1 11.1, CH3  0.82 11.1, CH3  0.82 
 2 22.8, CH2 1.52, m; 1.06, m 22.8, CH2  1.51, m; 1.08, m 
 3 37.1, CH 1.66, m 37.1, CH 1.67, m 
 4 15.0, CH3  0.86, m  15.0, CH3  0.86, m 
 5 72.5, CH 3.91, m 72.5, CH 3.94, m 
 6 172.6, C - 172.6, C - 
Pro 7 59.1, CH 4.84, m 59.1, CH 4.82, m 
 8 31.5, CH2  2.09, m 31.5, CH2  2.09, m 
 9 28.5, CH2  1.75, m 28.5, CH2  1.75, m  
 10 46.2, CH2  3.41, m 46.2, CH2  3.41, m 
 11 171.9, C - 171.9, C - 
Leu NH -  -  
 12 51.3, CH 4.35, m 51.3, CH 4.36, m 
 13 39.9, CH2  1.45, m 39.6, CH2  1.25, m 
 14 23.9, CH 1.53, m 23.7, CH 1.47, m 
 15 20.8-23.0, CH3  0.86, m 20.8-23.0, CH3  0.76, m 
 16 20.8-23.0, CH3 0.76, m 20.5, CH3  0.66, m 
 17 170.9-172.2 - -  
Pro 18 60.0, CH 4.25, m 59.7, CH 4.34, m 
 19 28.9, CH2  2.05, m 28.9, CH 2.05, m 
 20 24.1, CH2  1.78, m; 1.91, m 24.1, CH2  1.78, m; 1.91, m  
 21 46.4, CH2 3.67, m; 3.48, m 46.4, CH 3.65, m; 3.50, m 
 22 171.6 - 171.6 - 
Leu NH - 7.83, m - 7.84, m 
 23 48.6, CH 4.53, m 51.5, CH 4.17, m 
 24 39.6, CH2  1.45, m 39.6, CH2  1.48, m 
 25 23.6, CH 1.56, m 23.6, CH 1.51, m 
 26 20.8-23.0, CH3  0.87, m 20.8-23.0, CH3  0.82, m 
 27 20.8-23.0, CH3  0.87, m 20.8-23.0, CH3  0.87, m 
 28 170.3, C - 170.9-172.2, C - 
Leu NH - 8.00, d (8.3) - 8.15, m 
 29 51.6, CH 4.15, m 50.6, CH 4.21, m 
 30 40.9, CH2  1.41, m 40.0, CH 1.38 m 
 31 23.7, CH 1.50, m 23.7, CH 1.45, m 
 32 20.8-23.0, CH3  0.84, m 20.8-23.0, CH3  0.86, m 
 33 20.8-23.0, CH3  0.78, m 20.8-23.0, CH3  0.79, m 
 34 170.9-172.2, C - 170.9-172.2, C - 
Pho NH - 7.57, d (8.8) - 7.67, d (8.3) 
 35 52.6, CH 3.86, m 52.6, CH 3.86, m 
 36 62.4, CH 3.30, m; 3.25,m  62.36, CH 3.29, m; 3.21, m 
 37 36.5, CH 2.86, m; 2.67, m 36.5, CH 2.85, m; 2.65, m 
 38 139.0, C - 139.0, C - 
 39 128.6, CH 7.21, m 128.6, CH 7.21, m 
 40 127.7, CH 7.25, m 127.7, CH 7.25, m 
 41 125.5, CH 7.17, m 125.5, CH 7.14, m 
 42 127.7, CH 7.25, m 127.7, CH 7.25, m 





 fragment information for 9. Pho = phenylalaninol. MHP = 











 + 2H 457 
[Leu-Leu-Pho]
+ 
+ 2H 360 
[Leu-Pho]
+
 + 2H 247 
 
The relative configuration of 9 was determined by X-ray diffraction experiment 
on a single crystal prepared in a vapor diffusion chamber (acetone and ether).  
Compound 9 approximated a helix-like conformation in the crystalline state with the 
leucine residue side chains projecting outward from the compound in a relatively 
disordered state (Figure 4).  We observed a 3S*,5S*,7S*,12R*,18S*,23R*,29S*,35S* 
relative configuration for 9, which indicated that some of the incorporated amino acid 
residues possessed a D-configuration.  Marfey’s analysis was subsequently carried out 
demonstrating that both of the proline residues were L-configured (Supplemental Figure 
2).  In contrast, we detected a ~1:2 mixture of the Marfey’s-derivatized D and L 
leucines, which was in agreement with the proposed 12R*, 23R*, 29S* assignments for 
the three leucine residues detected in the crystal structure of 6 (Supplemental Figure 2).  
The Marfey’s analysis also provided definitive evidence for the presence of L-
phenylalaninol (Supplemental Figure 2).  Thus, the absolute configuration of compound 
9 was determined to be 3S,5S,7S,12R,18S,23R,29S,35S. 
42 
 
Figure 13. PyMol representations of 9. The top two views are rotated 180
o
. The bottom 
is a view of the helical wheel, looking down the center of the helix from the N-terminal. 
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The genome of B. laterosporus strain PE36 was reexamined to provide a link 
between the secondary metabolites made by this isolate and their respective 
biosynthetic genes.  Of the 11 NRPS gene clusters identified in PE36 (Table 2), cluster 
23 (Figure 5a) exhibited several distinctive features making it the likely source of 
metabolite 9.  Namely, cluster 23 contains an initial PKS-like initiation module that we 
postulate is responsible for loading the non-amino acid starter unit at the N-terminus of 
the 9.  This is followed by NRPS modules containing adenylation domains that are 
predicted to sequentially incorporate proline → leucine → proline → leucine → 
isoleucine → leucine → tyrosine → leucine → isoleucine → threonine.  The observed 
order of amino acids in 9, L-proline → D-leucine → L-proline → D-leucine → L-leucine 
→ L-phenylalaniol, fits fairly well with this prediction.  Upon closer inspection, 
epimerization domains are associated with each of the predicted leucine incorporation 
steps.  This explains the observed D-configurations of the first two leucines; however, 
the L-leucine origins are not clear.  We hypothesize that either the epimerization 
domain associated with the incorporation of the third leucine is not active or the third 
leucine incorporation module is skipped with the downstream isoleucine incorporation 
module, which lacks an epimerization domain, serving to install the third leucine.  The 
termination of the NRPS chain at the tyrosine/phenylalanine residue could occur via 
several scenarios including 1) phenylalanine incorporation followed by termination and 
post-production reductive tailoring , 2) tyrosine incorporation followed by termination, 
dehydroxylation, and reduction, or 3) full incorporation of all the predicted amino acids 
followed proteolysis of a tyrosine/phenylalanine → leucine bond. 
44 
Of the two predicted primarily PKS gene clusters (Table 2), biosynthetic cluster 
12 is the most likely candidate for the production of 4 and 5.  Cluster 12 is a predicted 
trans-AT PKS that also contains an NRPS-like domain (based on antiSMASH 
prediction).  Trans-AT PKSs are unique in a few key architectural and biosynthetic 
ways.  Most notably, each module lacks an AT (acetyltransferase) domain; instead the 
module receives its carbon building blocks from a shared AT, in this case a fused 
tandem AT domain 
76
.  Figure 5B illustrates the proposed biosynthetic gene cluster and 
plausible biosynthetic pathway responsible for the generation of 4 and 5.  The starter 
united is loaded by a predicted acetyl-loading AT of the GCN5-related superfamily 
(GNAT).  Each ketosynthase domain (KS) uses malonyl-CoA to add to carbon units to 
the growing polyketide chain.  Ketoreductases (KR), enolreductases (ER) and methyl 
transferases (MT) derivatize the chain to add hydroxyl and methyl groups.  The fourth 
module is split exhibiting a domain configuration of KS – KR – ACP – KS – DH – ACP 
– KR that is indicative of type B dehydrating bimodules.  These types of modules are 
capable of producing double bonds with either the E or Z configurations 
76
. 
The non-polyketide portions of 4 and 5 are likely introduced from three 
additional genes co-located with the gene cluster.  One of these genes was identified as 
a putative aminotransferase that could have converted a carboxylate into an amid 
77
.  
The cinnamic acid portion of the molecule is most likely added by an NRPS-like 
adenylation domain.  Adenylation domains have previously been shown to incorporate 
non-amino acid moieties into compounds via ester linkages 
78
. 
Mammalian microbiomes provide a unique opportunity to explore novel 
microbial biodiversity. As we have shown in this report, members of these microbial 
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communities contain the genetic machinery necessary to produce exciting natural 
products. Genomic characterization of a new strain of B. laterosporus, PE36, revealed a 
number of proposed secondary metabolite gene clusters. This information was used in 
conjunction with standard compound isolation and elucidation techniques to more fully 
explore PE36’s biosynthetic capabilities. As the field of natural products advances, and 
the need to access new biodiversity increases, mammalian microbiomes will be a vital 
resource in the search for new natural products. We have demonstrated that these 
microbial communities are an exciting source of new secondary metabolites. With 
continued attention and experimentation, mammalian microbiomes will be a rich and 




Figure 14. Graphical interpretation of antiSMASH results of auriprocine (9) and 
proposed biosynthesis of the polyketide portion of the basiliskamides A (4) and B (5). 
Panel A illustrates the biosynthetic gene cluster, cluster 12, responsible for the 
production 6. Adenylation domains are labeled with the amino acid they are predicted to 
contribute, with the N-terminal 6 carbon fragment’s unknown origin indicated with a ? 
in the corresponding adenylation domain. The two domains leading to the uncertainty of 
the L-leucine addition are contained in the indicated box and the two proposed 
hypothesis illustrated. Either the epimerization domain is inactive and the second 
domain skipped, or the first domain is skipped and the predicted isoleucine adenylation 
domain is instad adding a leucine. The remaining encoded domains that are not believed 
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to have contributed to the peptide are shown in grey. Panel B shows the organization of 
the proposed basiliskamide gene cluster.  The fused, tandem AT domains are shown 
separate from the rest of the modules.  The dehydrating bimodule is shown split, as the 
gene that encodes the two KS domains are separated from the dehydrogenase and 
ketoreductase.  The genes encoding the predicted aminotransferase, condensation, and 
adenylation domains (hypothesized to add the amide and cinnamic acid moieties to the 
polyketide chain) are labeled.  A: adenylation C: condensation, KR: ketoreductase, E: 
epimerization, GNAT: GCN5-related acetyltransferase, KS: ketosynthase, ER: 
enolreductase, MT: methyltransferase, DH: dehydrogenase, AT: acetyltransferase 
 
 
4.3 Materials and Methods 
4.3.1 Collection and bacteria isolation 
The oral, nasal and aural cavities of a recently deceased wild pig, shot by a 
hunter in southwest Oklahoma, were swabbed with a sterile cotton swab when the 
animal was brought in for processing at a local osteological processor in Oklahoma 
City, Oklahoma. The tip of each individual swab was removed and placed in a sterile 
15mL falcon tube containing 0.9% NaCl in water (w/v) solution. The tube was vortexed 
and diluted 1:10 with the salt solution. 50 uL was spread on half strength TSA. The 
streaked plates were incubated at 37
o
C and 5% CO2 for approximately two weeks. 
Individual colonies were picked based on color and morphological differences and re-
streaked on ½ strength TSA plates until pure colonies were obtained. 
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4.3.2 Overlay assay 
Bacterial isolates were arrayed onto half strength TSA plates and incubated for 
up to one week.  A layer of half strength TSA seeded with Staphylococcus aureus was 
genetly applied to the surface of each plate of isolations.  The plates were incubated at 
37
 º
C under a 5% CO2 atmosphere for five days and periodically examined for zones of 
inhibited S. aureus growth.  
 
4.3.3 DNA extraction, PCR amplification and sequence 
Genomic DNA was extracted using the PowerBiofilm DNA Isolation kit 
(MoBio Laboratories) by spinning down 2.0mL of turbid culture and following the 
manufacturer instructions.  The purity of gDNA was confirmed by spectrophotometery 
(Implen) and submitted to the Oklahoma Medical Research Foundation (OMRF) to be 
sequenced on a Illumina MiSeq using TruSeq LT 2x150bp chemistry.  Reads were 
assembled using the CLC Genomics Workbench suite de novo assembly algorithm.  
Contigs smaller than 800bp were discarded.  After assembly, scaffolded contigs were 
submitted to the RAST server for total-genome annotation 
79
.  These scaffolds were also 
uploaded to antiSMASH 
72
 to identify putative pathways associated with the production 
of secondary metabolites.  Pathway annotations identified by antiSMASH were 
amended to the RAST annotation prior to submission to GenBank.  Annotated gDNA 




4.3.4 Culture conditions and extractions 
A starter culture of the bacterium was prepared in tryptic soy broth (TSB) and 
shaken on a rotary shaker at 130 rpm for 12hr.  One liter flasks (Erlenmeyer) containing 
300 mL of autoclaved TSB were inoculated with 1 mL of starter culture.  The flasks 
were shaken at 130 rpm at room temperature for 1 week.  The culture was transferred to 
a glass extraction vessel for partitioning. The culture was partitioned three times against 
EtOAc (1:1 vol/vol) and the solvent removed from the organic layer under reduced 
pressure on a rotary evaporator. 
 
4.3.5 Compound isolation 
The crude extract (approximately 4g from 30L culture) was absorbed onto silica 
and subjected to fractionation by flash chromatography using a hexane-CH2Cl2-MeOH 
gradient. Isolation of each compound was as follows: 
 
The crude extract (~4g from 30 L culture) was absorbed onto silica gel and 
subjected to flash chromatography fractionation using a hexane-CH2Cl2-MeOH 
gradient. The final purification of each compound was achieved as follows: 
 
12-methyltetradecanoic acid (6):  A silica flash column was run (Hexane:DCM:MeOH) 
and the fraction that eluded with 100% DCM was further separated using C18 HPLC.  A 
MeOH-H2O gradient (20% MeOH for 5 minutes, 20-100% MeOH gradient over 50 
minutes, 100% MeOH for 10 minutes at a 10 mL/min flow rate) resulted in a single 
active fraction.  This fraction was further purified by semi-preparative HPLC (60% 
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ACN for 10 minutes, 60-100% ACN gradient over 45 minutes, 100 % ACN for 10 
minutes at 2 ml/min) to provide 6.  The structure of the metabolite was confirmed by 
1
H 
NMR and GC-MS analysis. 
 
Basiliskamides A (4) and B (5): C18 VLC (75:25, 50:50, 25:75, 100% Water:MeOH) 
was run and the fraction that eluded with 100% MeOH was further separated using C18 
HPLC.  A MeOH-H2O gradient (20% MeOH for 5 minutes, 20-100% MeOH gradient 
over 50 minutes, 100% MeOH for 10 minutes at a 10 mL/min flow rate) resulted in a 
single active fraction.  This fraction was further purified by semi-preparative C18 HPLC 
(isocaratic, 80% MeOH) to yield 4 and 5.  The compounds were identified based on 




2,5-bis(3-indolylmethyl)pyrazine (7): An HPLC fraction that eluted following 4 and 5 
was further purified by semi-preparative C18 HPLC (60% MeOH for 5 minutes, 60-
100% MeOH over 50 minutes, 100% MeOH for 10 minutes at a 10 mL/min flow rate) 





Auripyrazine (8): A fraction eluting from HPLC prior to 4 and 5 was further purified by 
preparative C18 HPLC (20% MeOH for 5 minutes, 20-100% MeOH gradient over 50 
minutes, 100% MeOH for 10 minutes at a 10 mL/min flow rate).  Further purification 
by semi-preparative C18 HPLC (isocratic, 40% acetonitrile with 0.1% formic acid) 
provided purified 5. 
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Auriporcine (9): A very late eluting fraction from the same HPLC purification step that 
yielded 4 and 5 was pursued for further analysis.  Semi-preparative C18 HPLC with 
acetonitrile and H2O treated with 0.1% TFA (10% acetonitrile for 5 minutes, 10-100% 
acetonitrile gradient over 55 minutes) provided purified 9. 
 
4.3.6 Marfey’s analysis of auriporcine 
Marfey’s analysis was performed as described in 
81
, with slight modifications. 
Briefly, approximately 1 mg of 9 was dissolved in 6M HCl and heated at 100
o
C for 
approximately 18 h. After heating, the sample was dried under reduced pressure, 
redissolved in 50 µL of water and transferred to a 1.5 mL centrifuge tube. 50 µL of 50 
mM D and L-enantiomenrs of each amino acid of interest was aliquoted into 1.5 mL 
centrifuge tubes. To each standard and sample, 100 µL of 1% FDAA and 20 µL of 1M 
NaHCO3 was added. Tubes were capped and heated in a 40
o
C water bath, with periodic 
mixing, for 1 h. After cooling to room temperature, 10 µL of 2M HCl was added to 
each tube. The mixtures were dried under reduced pressure and redissolved in 200 µL 
of 90:10 MeOH:Water. Samples were diluted 1:10 with 90:10 MeOH:water for LCMS 
analysis. 
 
4.3.7 X-ray experimental information 
A colorless prism-shaped crystal of dimensions 0.440 x 0.160 x 0.120 mm was 
selected for structural analysis. Intensity data for this compound were collected using a 
diffractometer with a Bruker APEX ccd area detector and graphite-monochromated Mo 
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Kα radiation (λ = 0.71073 Å). The sample was cooled to 100 K. Cell parameters were 
determined from a non-linear least squares fit of 6210 peaks in the range 2.41 < θ < 
26.04°. A total of 40661 data were measured in the range 1.554 < θ < 28.344° using ϕ 
and ω oscillation frames. The data were corrected for absorption by the empirical 
method giving minimum and maximum transmission factors of 0.964 and 0.990. The 
data were merged to form a set of 10800 independent data with R(int) = 0.0586 and a 
coverage of 99.9 %. 
The orthorhombic space group P212121 was determined by systematic absences 
and statistical tests and verified by subsequent refinement. The structure was solved by 
direct methods and refined by full-matrix least-squares methods on F
2
. The positions of 
hydrogens bonded to carbons were initially determined by geometry and were refined 
using a riding model. Hydrogens bonded to nitrogens and oxygens were located on a 
difference map, and their positions were refined independently. Non-hydrogen atoms 
were refined with anisotropic displacement parameters. Hydrogen atom displacement 
parameters were set to 1.2 (1.5 for methyl) times the isotropic equivalent displacement 
parameters of the bonded atoms. A total of 573 parameters were refined against 118 
restraints and 10800 data to give wR(F
2
) = 0.1925 and S = 1.011 for weights of w = 
1/[σ2 (F
2
) + (0.0900 P)
2




] / 3. The final R(F) was 
0.0707 for the 9029 observed, [F > 4σ(F)], data. The largest shift/s.u. was 0.012 in the 
final refinement cycle. The final difference map had maxima and minima of 0.315 and -
0.374 e/Å
3
, respectively. The absolute structure could not be determined by refinement 
of the Flack parameter. 
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4.3.8 Compound characterization 




C data see 
Table 2; HRESIMS [M-H]
-
 m/z 222.1039 (calculated for C14H12N3, 222.1031). 




C data see Table 3; HRESIMS [M+H]
+
 m/z 799.5330 (calculated for 
C43H71N6O8, 799.5333). 
 
4.4 General experimental conditions 
UV data were collected on a Hewlett Packard 8452A diode array 
spectrophotometer. Optical rotation data was determined on an AutopolIII automatic 
polarimeter. UV–CD spectra were measured on an AVIV circular dichroism 
spectrometer model 202-01. NMR data were obtained on Varian VNMR spectrometer 
(500 mHz).  Accurate mass data were collected on an Agilent 6538 HRESI QTOF MS 
coupled with an Agilent 1290 HPLC. LCMS analysis were performed on a Shimadzu 
LCMS 2020 system (ESI quadrupole) coupled to a photodiode array detector, samples 
were separated using a Phenomenex Kintex column (2.6 µm C18 column, 100 Å, 75 x 
3.0 mm). The HPLC system utilized SCL-10A VP pumps and system controller with a 
Gemini 5 μm C18 column (110 Å, 250 × 21.2 mm, flow rates of 1 to 10 mL/min). X-ray 
data were collected using a diffractometer with a Bruker APEX ccd area detector and 





Chapter 5. A high-throughput screening procedure of mammalian 
microbiome isolates for secondary metabolite production, 
antimicrobial activity and cancer cell cytotoxicity 
 
5.1 Introduction 
5.1.1 Accessing new biodiversity in the search for new natural products 
  Natural products are widely considered the future of drug discovery.
33
 These 
small molecules, isolated primarily from marine and terrestrial derived plants, fungi and 
bacteria, produce and inspire a staggering number of current pharmaceutical products. 
4
  
In order to continue to have such a strong impact on pharmaceutical research, and entice 
pharmaceutical companies away from a more synthetically driven approach,
4
 there 
exists a continual need to  access new biodiversity. Despite being a vital part of 
discovering natural product chemistry, 
35
 access to new biodiversity is often a challenge.   
 This need to access new biodiversity, and overcome some common issues in 
natural products research, has led us to consider exploring the mammalian microbiome 
as a source of novel microorganisms. Animal microbiomes are a virtually unexplored 
source of bacterial and archaeal diversity. Bacteria associated with other bacteria, 
plants, fungi, nematodes, insects and sponges produce an array of interesting and 
biologically active secondary metabolites. 
36
 Bacterial symbionts of larger mammals, 
such as humans, have been shown to produce a variety of natural products,
66
 and we can 
expect the microbial communities of smaller mammals to be similarly biosynthetically 
talented. In this case, investigating the mammalian microbiome as a source of new 
natural products is an attractive solution to the inherent problems of sample collection. 
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The challenge is effectively isolating and screening these organism for secondary 
metabolite production.    
 
5.1.2 Screening approach for biosynthetically talented bacteria 
Screening of crude extracts in our in-house assay procedure has proven to be an 
effective method for identifying biosynthetically talented organisms. LCMS traces of 
crude extracts were considered in tandem with in vitro activity against methicillin-
resistant Staphylococcus aureus (MRSA), Candida albicans, and a human pancreatic 
cancer cell line. Together, this information created a comprehensive data set to 
determine whether to pursue an organism for further work. The organizational goals for 
the screening project were to establish a method that quickly and efficiently identified 
organisms worth pursuing further and minimized hands-on time for a researcher. These 
goals were accomplished by biasing the method towards the most productive organisms. 
This was accomplished by limiting the liquid media to only three types: one nutrient 
rich medium (tryptic soy broth) and two defined media with minimal nutrients. The 
minimal media were chosen to stress the organism by providing a minimal amount of 
nutrients necessary for it to survive and induce the production of secondary metabolites.  
 The downside to this approach is the potential to miss interesting secondary 
metabolites by selecting for the organisms that are easiest to grow in liquid culture. 
However, new isolates are cheap and comparatively easy to obtain. It is more efficient 
to collect additional isolates that easily produce metabolites in the lab than it is to tease 
secondary metabolites out of each organism that is isolated. By limiting the media and 
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growth conditions, the focus is shifted towards organisms with a greater potential to 
produce more metabolites in lab conditions.  
Finally, efficiency was also addressed through the use of a liquid handling robot 
to perform the extraction procedure on the liquid bacteria cultures, as shown in Figure 
15. When coupled with automated solvent drying systems, the hands on time required 
by a researcher is reduced from hours to minutes. The liquid handling robot is 
programed to add EtOAc to each culture tube and allow each sample culture to extract 
for one hour. A conductivity sensing feature is used to remove only the organic layer 
and deposit the solvent into a clean 96 well plate. By using the liquid handling robot 
during the extraction phase of this protocol, a group could extract 300-400 cultures in a 
typical 8 hour work day.  
 
 
Figure 15. Automated liquid handling robot from Aurora Biomed 
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5.1.3 Purification of organisms 
While the mammalian microbiome has proven to be a rich and diverse source of 
microorganisms, there will inevitably be some organisms that grow faster than others. 
These organisms tend to spread out quickly, monopolize the space on a petri plate and 
decrease the diversity of organisms on any given plate. Ultimately, the isolation 
conditions were chosen to inhibit some of these faster growing organisms. By using 
hypoxic conditions during the initial isolation phase, a greater diversity of organism 
types was seen. By choosing one growth condition, we improved efficiency but 
potentially limited our final results. From our experiments, the benefits of this initial 
plate diversity outweighed the chance of missing a select few organisms and improved 
overall efficiency.  
Two plate types were used in this protocol for the initial plating of microbiome 
samples, 10% strength TSA and BHI, with the salt concentrated adjusted to the levels of 
a full strength mixture. Individual colonies were chosen for further purification based 
on unusual characteristics such as color, growth patterns, and incubation period before 
growth is observed. Isolates were restreaked onto the similar plate types for further 
purification. The media used for an organism’s isolation was noted and used for later 
grow ups for DNA extraction and cryogenic storage.  
 
5.1.4 Selection of animals for sampling 
 It should be noted that selection of the mammals to study is extremely 
important. Since the animals being sampled were already deceased by other causes, 
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there existed the potential of sampling opportunistic environmental bacteria instead of 
the natural microbial community of the animal. For animals that have died due to being 
hit by vehicles, it is best to sample in the hours just after sunrise. Nocturnal animals 
were most likely hit no more than a few hours prior. In warmer months, early morning 
collection ensures microbial colonization by other organisms is not sped up by ambient 
heat.  
 Visual inspection of the animal was necessary, and carcasses with bloating, 
insect infestation or removal of flesh from scavengers were not chosen for sampling. 
Additionally, a manner of death could sometimes be deduced by looking at the corpus. 
Animals that expired due to substantial internal injuries to the gut were rejected as 
candidates for intestinal sampling. The ideal carcass for microbiome sampling would 
have all the visual cues of a recent death and minimal damage to the main body cavity. 
Excessively bloodied orifices were not sampled. Figure 16 demonstrates ideal sampling 
conditions. These steps ensured that the samples collected were representative of the 
native microbial community and not of opportunistic environmental organisms 
colonizing the animal after its death.  
 Finally, the legality of collecting deceased roadside animals was investigated for 
our sampling area. Collection of samples required a permit from the town government. 




Figure 16. A skunk (top panel) is sampled roadside. An armadillo (bottom panel) was 
opened to access the large and small intestines. Both carcasses have all visual signs of a 
recent death. The main body cavities are intact and there is minimal bleeding from 
sampled offices.  
  
5.1.5 Interpretation of LCMS data 
 Evaluation of the LCMS data required the largest amount of hands on 
involvement. Accurate interpretation of the generated spectra is vital to the success of 
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this protocol. The PDA and mass spectrum data was evaluated in tandem to determine 
whether an organism is biosynthetically talented. Typically, spectra that are 
dramatically different than the baseline chromatograms of the media control are easily 
identified. As previously described, the objective of this method is to quickly identify 
the most prolific natural product producers, and not be concerned with missing less 
productive organisms. As shown in Figure 17, the most talented organisms will produce 
crude extracts with chromatographic profiles that are clearly different than controls and 
other less talented organisms.   
 
 
Figure 17. Illustration of generated LCMS data. A biosynthetically talented strain (red 
trace) compared to a less talented strain (blue trace) and the media control (black trace). 
Chromatogram shown 0-10 minutes for ease of viewing.  
 
 






Controls are relatively straightforward for this procedure. As space permitted, 1-
3 tubes of each liquid media type were left un-inoculated. These tubes were placed on 
the shaker with the inoculated broths. The culture blanks remained clear with no signs 
of microbial growth, indicating contamination of the samples by environmental 
organisms was unlikely. The culture blanks were than extracted along with the 
inoculated cultures and used as a comparison during chromatographic analysis.   
During bioactivity assays, chloramphenicol and fluconazole (100µg/mL each in 
DMSO) were used as positive controls to qualitatively determine the level of bioactivity 
seen in a crude extract. DMSO, the solvent used to dissolve each crude extract and the 




 All reagents are cell culture grade unless otherwise stated.  
 Water (deionized) 
 EtOAc 
 DMSO 
 Tryptic Soy Broth (TSB), premade powder 



























 Chloramphenicol  
 Fluconazole  
 Acetonitrile (LCMS grade) 
 Water with 0.1% formic acid (LCMS grade) 
 Methanol (LCMS grade) 
 C. albicans cell line ATCC 38245, frozen in 20% glycerol 
 S. aureus cell line ATCC 700787, frozen in 20% glycerol 
 MIA PaCa-2 cells ATCC CRL-1420 
 YM media 
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 Stir plate 
 Magnetic stir bar 
 pH meter 
 Sterile swaps 
 Large scalpel 
 Small scalpel, sterile 
 15 mL polypropylene tubes, sterile  
 Vortexer  
 Pipettes (capable of pipetting 200, 100 and 50 µL) 
 Appropriate pipette tips, sterile 
 Hypoxic chamber 
 Petri dishes, 100x15 mm, sterile 
 Culture tubes, 16x100 mm, sterile 
 Caps for 16x100 mm tubes 
 Rotary Shaker, with rack capable of holding 16x100 mm culture tubes 
 Deep well 96 well plates 
 Evaporator capable of drying 96 well plates under reduced pressure (Genevac, 
EZ-2 series) 
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 Cryogenic tubes 
 Centrifuge, capable of centrifuging at 10,000 x g 
 Refridgerator, 4oC 
 Freezer, -80oC 
 Sonicator 
 250 mL Erlenmeyer flask 
 250 mL separatory funnel 
 250 mL round bottom flask 
 Rototary evaporator 
 Scintillation vials 
 Speedvac evaporator 
 LCMS system (Shimadzu 2020, ESI quadrupole,   photodiode array detector, 
autosapler with 96-well plate tray, Phenomenex Kinetex column, 2.6 µm C18, 
100Å, 75 x 3.0 mm) 
 Incubator (37oC, 5% CO2, humidified) 
 Plate reader (capable of determining OD600) 
 96-well plate for biological assay, capable of being used in plate reader 
 
5.2.4 Reagent setup 
 
Phosphate buffer solution (PBS) 
 Combine the following with 1L of water, all eights in grams: NaC (8), KCl 
(0.2), Na2HPO4 (1.78), KH2PO4 (0.27). Stir on a magnetic stir plate with a magnetic stir 
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bar until dissolved. Adjust pH to 7.4. Dispense 5 mL into 15 mL conical tubes and 
autoclave. Allow to cool to room temperature.  
  
TSB Broth 
 Prepare full strength TSB according to the manufacturer’s instructions by 
mixing 30g of product and 1L of distilled water. Mix on a magnetic stir plate with a 
magnetic stir bar until fully dissolved. For small scale analysis, dispense 2 mL into 
16x100 mm culture tubes and cap. For biological assay, put 50 mL in a 250 mL 
Erlenmeyer flask and cover with foil. Autoclave and allow to cool to room temperature 
before use. This solution is stable indefinitely at room temperature if firmly sealed.  
 
 
Minimal Media A 
 Media adapted from Rateb, et al.
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 Combine the following with 1L of distilled 
water (all weights in grams): KH2PO4 (2.0), NH4Cl (1.5), MgSO4·7H2O (0.5), glycerol 
(10), myo-inositol (0.4), monosodium L-glutamate monohydrate (5.0), NaF (0.084), 
FeSO4·7H2O (0.025), ZnSO4·7H2O (0.01), CoCl2·6H2O (0.01), CaCO3 (0.25), p-
aminobenzoate (0.001). Mix using a magnetic stir plate and magnetic stir bar. Adjust 
pH to 7.0. For small scale analysis, dispense 2 mL into 16 x 100 mm culture tubes and 
cap. For biological assay, put 50 mL in a 250 mL Erlenmeyer flask and cover with foil.  
Autoclave and allow to cool to room temperature. This solution is stable indefinitely at 
room temperature if firmly sealed.  
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Minimal Media B 
 Combine the following with 1L of distilled water (all weights in grams): 
Glycerol (15 mL), L-glutamine (5), K2HPO4 (1.5), MgSO4 (0.2). Mix on a stir plate with 
a magnetic stir bar until completely dissolved. Adjust the pH to 7.0. For small scale 
analysis, dispense into 16x100 mm culture tubes and cap. For biological assay, put 50 
mL in a 250 mL Erlenmeyer flask and cover with foil.  Autoclave and allow to cool to 




 Mix 3g of TSB powder with 15g of agar and 4.5g of NaCl with 1L of distilled 
water. Mix on a magnetic stir plate with a magnetic stir bar. Autoclave in an appropriate 
container and allow to cool enough to handle. Pour into sterile petri dishes. Allow to 
cool completely. Store at 4
o
C indefinitely.  
 
BHI Agar 
 Mix 3.7g of BHI powder with 15g of agar and 4.5g of NaCl with 1L of distilled 
water. Mix on a magnetic stir plate with a magnetic stir bar until dissolved. Autoclave 
in an appropriate container and allow enough to handle. Pour into sterile petri dishes. 
Allow to cool completely. Store at 4
o






 Mix 21g of YM powder with 1L of distilled water. Mix on a magnetic stir plate 
with a magnetic stir bar until dissolved. Autoclave in an appropriate container and allow 
to cool to room temperature before use.  
 
Positive control stocks for bioassay 
 Prepare 10 mg/ml stock solution in DMSO of chloramphenicol and fluconazole.  
 
5.2.5 Cell preparation for biological assays 
 Thaw fungal or bacteria cell lines and dilute with YM media (fungi) or TSB 
(bacteria), 20 µL of cells with 11 mL of media. Dispense stocks into an appropriate 
number of wells in a 96 well plate, 100 µL per well. 
 For cancer cells, add 10,000 MIA PaCa-2 cells in an appropriate number of 
wells in a 96-well plate. Allow cells to attach overnight in a 37
o
C incubator with a 5% 
CO2 atmosphere.  
 
5.2.6 Equipment setup 
 
Aurora Biomed liquid handling robot 
 The Aurora Biomed liquid handling robot is used for dispensing organic solvent 
(EtOAc) into each culture. After a brief extraction period, the robot uses conductivity 
sensing to remove the organic layer from the top of each culture and transfers it to a 96 
well plate. Program the instrument for your specific arrangement of plate and rack 
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holders. Dispense 1.5 mL of EtOAc into each culture broth and set a 1 h wait time 
before removal to a 96 well plate.  
 
Shimadzu LCMS: ESI single quad MS, PDA detector, autosampler outfitted with 
96well plate track holder 
 The Shimadzu LC2020 series LCMS is used for generating PDA and mass 
chromatograms of crude bacteria culture extracts. Calibrate your particular autosampler 
to aspirate 10 µL from each well. Use the software to program a 17 minute analysis. For 
the mass spectrometry analysis, set up two events, one for positive ion detection and 
one for negative ion detection. Set both events to scan m/z 200-1500. Program the PDA 
to scan the entire available wavelength, from 190-800 nm. Set up the gradient as per 
Table 5, which allows for a relatively complete separation of all components and 
incorporates a column equilibration step. Solvent A is water with 0.1% formic acid, 
Solvent B is ACN (see Reagents section) 
 
Table 6. Gradient scheme for LCMS separation of crude extracts 
 
Time B concentration 
1 min 10 
13 min 100 
15 min 100 
15.01 min 10 






Sampling of deceased mammals (timing: 1-2 hours) 
CAUTION: Use appropriate personal protective equipment while sampling animal 
carcasses 
1. Locate carcasses that meet the criteria described in 5.1.4. Use a sterile swab and 
sample the oral, nasal, aural, anal and vaginal (if present) cavities.  
2. Use a sharp scalpel to open the body cavity and locate the large and small 
intestines. Using a sterile scalpel, make a small incision in the intestines and 
swipe inside with a sterile swab.  
3. Put swabs in a tube with 5 mL sterile PBS, breaking off the stick if necessary to 
fit in the tube.  
4. Store at 25oC until plating. 
 
Plating of samples (timing: ~3 days) 
5. Vortex each tube for approximately 15 seconds.  
6. From each sample tube pipette 200, 100, and 50 µL aliquots onto separate plates 
of each media type. (If using two plate types, there will be 6 plates per sample 
swab) 
7. Grow plates in a hypoxic chamber (N2:O2:CO2 1%:1%:98% (vol/vol)) for 36 
hours. 
8. Visually identify individual colonies and restreak onto new plates. Repeat the 
process as necessary to obtain pure cultures. 
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9. Once pure, remove plates from hypoxic chamber and allow to grow aerobically 
at 25
o
C for 36 hours.  
 
Glycerol stocks (timing: ~ 3 days) 
10. After aerobic growth is observed, inoculate each pure bacterium into 5mL of 
sterile broth, corresponding to the solid medium used for its isolation. 
11. Shake at 250 rpm for 36 hours.  
12. After the growth period, dilute the remaining culture with 8.5:10 with glycerol. 
13. Transfer a small aliquot to a cryogenic tube and free at -80oC for storage. 
 
Small scale cultures (~3 hours per plate) 
14. Scrape a small amount of purified organism off of each plate and inoculate a 
tube containing 2 mL of autoclaved medium. Cap securely.  
15. Shake at 250 rpm for 36 hours. 
16. Record qualitative observations after 36 hours on hardiness of growth, color, or 
other visual observations. 
17. Use the Aurora liquid handler to extract cultures using EtOAc. Cultures should 
extract for at least one hour before allowing the robot to remove the EtOAc and 
distribute it into a clean 96-well plate. 
18. Dry the plate containing the extract under reduced pressure. 
 
LCMS analysis of crude extracts (17 minutes per sample, ~27 hours per plate) 
19. Add 100 µL of 90:10 MeOH:water to each well. 
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20. Sonicate briefly to ensure extract is fully dissolved 
21. Load the 96-well plates into LCMS autosampler if available or transfer samples 
into the appropriately sized vials for your autosampler.  
22. Analyze samples using the gradient  and instrument settings described in section 
5.2.4. 
23. Analyze samples as described in section 5.1.5. Identify with organisms are 
prolific natural product producers. 
 
Preparation of samples for biological assay (~3.5 days) 
24. Innoculate 50 mL of the appropriate broth with any organisms identified in the 
screening procedure as being biosynthetically talented.  
25. Shake on a rotary shaker at 250 rpm for 3 days. 
26. Add 50 mL of EtOAc and let sit for 1 hour. 
27. Remove organic layer using a separatory funnel. Put in a round bottom flask and 
dry on a rotary evaporator.  
28. Transfer extract to a tared scintillation vial and dry using a speedvac evaporator.  
29. Create a stock solution for analysis, 10 mg/mL for antimicrobial assays, 1 mg/ml 
for cancer call cytotoxicity. 
 
Antimicrobial bioassay (~24-48 hours) 
30. Dissolve crude extracts to a concentration of 10 mg/mL in DMSO for 
antimicrobial assays, 2.5 mg/mL for cancer cell cytotoxicity 
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31.  1 µL of crude extract solution or positive control stock solution is added to each 
well (concentration of 100 µg/mL for antimicrobial assays, 25 µg/mL for cancer 
cell cytotoxicity). Add 1 µL of 100% DMSO to 3 wells to use for blank 
correction. Plates are shaken orbitally for 5 seconds. 
32. Initial OD600 readings are obtained for antimicrobial assays.  
33. Fungal strains are incubated 48 hours in a humidified incubator at 37oC and 5% 
CO2. Bacteria strains and cancer cells are incubated for 24 hours at the same 
conditions.  
34. At the conclusion of the incubation period, bacterial and fungal plates are 
shaken orbitally prior to obtaining OD600 readings. The final OD600 is 
substracted from the initial OD600 to obtain the change in OD600 reading. 
35. After incubation, cancer cell viability is determined by MTT assay.74  
 
5.4 Anticipated results 
 The majority of organisms sampled will not be biosynthetically talented 
organisms under protocol conditions, and thus most LCMS traces observed will be 
relatively unexciting compared to the media controls. In our experience, the hit rate by 
LCMS analysis averages approximately 10%, with screenings sometimes greatly 
deviating from the norm in both directions. However, of these organisms designated as 
biosynthetically talented, the hit rate in biological assays is approximately 75% or 
greater. This implies that an organism with an interesting metabolic profile by LCMS 
has a strong likelihood of producing biologically active compounds. Consequently, this 
is a sensitive method for isolating and screening organisms from the mammalian 
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microbiome for prolific natural product producers. The method is applicable to any 
deceased small mammal that is available for sampling and can be easily adjusted to 
include more specialized and selective media types. As written, this is an efficient 
method for screening large amounts of symbiotic bacteria that requires little hands on 
time for researchers. It makes use of robotics and instrumentation to increase the 
number of organisms that can be screened at one time beyond what an individual 
research can perform in any given day.  
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Discussion A1. Explanation of Marfey’s analysis 
Peptides are comprised standard and non-standard amino acids. These amino 
acids consist of an amine group, an α-carbon with a pendant group and carboxylic acid. 
Amino acids can exist in one of two isomer forms, L or D (figure M1) L-amino acids 
are almost exclusively used in protein production in animals and humans, although 
there are a few exceptions for D-amino acids playing biological roles in humans and 
other animals.
41
 D-amino acids, can frequently be found in bacteria, especifically in 




Figure M1. L and D-amino acids.  
 
A common method to determine the chirality of amino acids is through 
chromatographic separation of their diastereomers. Amino acids are derivatized with an 
enatiomerically pure reactant and then separated by HPLC chromatography. The 
reactant used typically has a good chromophore, to enhance detection by HPLC UV 
detectors and is relatively “bulky” to enhance resolution. In chapter 4, the absolute 
configuration of auriprocine was determined through a method known as Marfey’s 
analysis. Using this method, the peptide of interest was hydrolyzed to yield its 
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individual amino acid components and each amino acid is then derivatized with 1,5-
difluro-2,4-dinitrophenyl-5-L-alanineamide (FDAA), most commonly referred to as 
Marfey’s reagent. The result of this reaction, shown in figure M2, is either the LL or LD 
diastereomer of the precursor amino acid. Under the correct chromatographic 
conditions, these derivatized amino acids will have different retention times. By 
comparing the retention times of appropriate amino acid standards, the configuration of 
each amino acid in the can be determined.  
 
  
Figure M2. Marfey’s reagent, and derivatized amino acid diastereomers 
The separation of diasterometic pairs is generally preferred to more direct 
methods (i.e., enantiomer separation), as it is often simpler to optimized 
chromatographic conditions, and does not require columns with chiral stationary phases. 
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However, there are a few disadvantages to this method. Amino acids such as tyrosine or 
histidine or those that contain two amino groups, can form both mono and disubstiuted 
derivatives. This is generally overcome through the use of excess Marfey’s reagent, 
minimizing the amount of mono-substituted compound. Additionally, depending on the 
conditions used during hydrolysis, some racemization can occur. By running the full 
hydrolysis reaction of the standard amino acids as well as a sample can aid in 
determining if epimerization is occurring. Finally, depending on chromatographic 
conditions, peaks can sometimes overlap in the UV profile, making analysis more time 
consuming as chromatographic conditions must be manipulated. However, as was the 
case with auriprocine in chapter 4, this can be avoided by using an LCMS. By 
extracting the mass data for each derivatized amino acid, overlapping peaks in the UV 
will often resolve to allow the determination of retention times. 
 
Figure M3. Single ion traces of derivatized amino acids, illustrating the resolution 





Discussion M2. Proteasome inhibition assay 
The proteasome is a large (700 kDa) cylinder-shaped proteinase complex that is 
involved in the degradation of intercellular proteins.
40
 The proteasome is made up of 35 
different subunits, with the proteolytic core complex residing in the 20s proteasome.
37
 
The proteasome is responsible for degrading a range of intercellular proteins, involved 
in cell cycle control, singal transduction, transcription factors, oncogenes and oncogene 
products. 
40
 Although protein degradation is vital to the survival of a cell, proteasome 
inhibitors exhibit anti-inflammatory and antiproliferative effects, making the search for 
proteasome inhibitors an exciting area of research. 
In chapter 3, the glidobactin and luminmycin family of compounds were shown 
to be proteasome inhbitors, the effect of which was studied through the use of a kit 
purchased from Cayman Chemical (kit number 10008041). The kit employs a 20s 
subunit substrate, N-Succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin (SUC-
LLVY-AMC), which when cleaved by the proteasome releases a highly fluorescent 
product. If the proteasome is active, the SUC-LLVY-AMC will be cleaved, and the 
fluorescence can be measured at 360 and 480 nm, excitation and emission wavelengths, 
respectively. Proteasome inhibitors will show a decrease in fluorescence dependent on 
the concentration of the inhibitor present 
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Table A1. Summary of antiSMASH results of the P. asymbiotica ATCC43949 genome. 
Putative gene clusters for secondary metabolites and their genomic locatins are shown. 
Cluster 15 was identified as homologous to the genes responsible for glidobactin 









































Table A2. Summary of media types explored to induce the production of 
glidobactins/luminmycins. 
Name Formulation Compounds 
induced 
TSB Commercially available - 
TSB plus chitin 





TSB plus soil 
Commercially available mix with 10% v/v soil 
extract added prior to autoclaving 
- 
TSB plus blood 
Commercially available mix with 5% v/v sterile 
sheep blood added after autoclaving 
- 
TSB plus bugs 
Commercially available mix with 3 ground bugs 
collected in Norman, OK added to 300 mL of 
broth prior to autoclaving 
- 




: dextrose ( 1.7), tryptone (27), NaCl (5), 
K2HPO4(2.5) 
- 





: dextrose ( 1.7), tryptone (27), NaCl (5), 
K2HPO4(2.5) 
- 
TSB mimic, glucose In gL
-1
: glucose (2.5), tryptone (20), NaCl (5), 
K2HPO4(2.5) 
- 
TSB mimic, ribose In gL
-1
: ribose (2.5), tryptone (20), NaCl (5), 
K2HPO4(2.5)  
- 
TSB mimic, sucrose In gL
-1
: sucrose (2.5), tryptone (20), NaCl (5), 
K2HPO4(2.5) 
- 
Actinomyces broth Commercially available - 
Potato dextrose Commercially available 1 
Luria broth Commercially available 1 
Luria broth plus 
homogenized bugs 
Commercially available mix with approximately 
10 bugs collected in Norman, OK added to 300 
mL of broth and homogenized with mechanical 




  In gL
-1
: KH2PO4 (2.0), NH4Cl (1.5), 
MgSO4
.
7H2O (0.5), glycerol (10), myo-insitol 
(0.4), monosodium L-glutamate monohydrate 







6H2O (0.01), CaCO3 
(0.25), p-aminobenzoate (0.001)
 
1, 2, 3 
Defined medium, 
honey as carbon 
source 
Same as defined medium but with 10gL
-1
 of 
honey in place of glycerol 
1, (trace amounts 
of 2 and 3) 
Defined medium, 
sucrose as carbon 
source 
Same as defined medium but with 10gL
-1
 of 
sucrose in place of glycerol 
1, (trace amounts 
of 2 and 3) 
Defined medium, 
glucose as carbon 
source 
Same as defined medium but with 10gL
-1
 of 
glucose in place of glycerol 
1, 2, 3 
Defined medium, 10% 
v/v sheep blood 
Same as defined medium, with the addition of 
10% v/v of sterile sheep blood added after 
autoclaving 
1, 2, 3 
94 
0.25x seawater In gL
-1
: NH4Cl (1.5), glycerol (10), monosodium 
L-glutamate monohydrate (5), instant ocean (8.8) 
- 
0.5x seawater In gL
-1
: NH4Cl (1.5), glycerol (10), monosodium 
L-glutamate monohydrate (5), instant ocean 
(17.5) 
- 
1x seawater In gL
-1
: NH4Cl (1.5), glycerol (10), monosodium 






Sterile, filtered, commercially available 1 
DMEM plus 5% fetal 
bovine serum (FBS) 
Sterile, filtered, commercially available DMEM 
and FBS added at 5% v/v 
- 
DMEM plus glycerol In gL
-1
: glycerol (10). Autoclaved and mixed 
with sterile, filtered, commercially available 
DMEM 
1 
DMEM plus glycerol 
and 5% FBS 
In gL
-1
: glycerol (10). Autoclaved and mixed 
with sterile, filtered, commercially available 
DMEM and 5% v/v FBS 
- 




: plant food, commercially available water 
soluble (1.6), glycerol (10) 
1 
Plant food plus sucrose In gL
-1
: plant food, commercially available water 
soluble (1.6), sucrose (10) 
1 




: plant food, commercially available water 
soluble (1.6), glucose (10) 
1 
Plant food plus honey In gL
-1
: plant food, commercially available water 
soluble (1.6), honey (10) 
1 




: plant food, commercially available water 
soluble (1.6), cholesterol (10) 
- 
Skim milk  In gL
-1
: skim milk powder (10) - 




: skim milk powder (10), glycerol (10) - 
 
Compound 1 : Glidobactin A; Compound 2: Luminmycin A; Compound 3: 
Luminmycin D;  
a 









Table A3. Crystal data and structure refinement for auriprocine, 9 
 
Emperical formula C43H70N6O8 
Formula weight 799.05 
Crystal system Orthorhombic 
Space group P212121 
Unit cell dimensions a = 11.1021(10) Å α = 90
o 
 b = 14.9391(14) Å β = 90
o
 





Z,Zʹ 4, 1 
Density (calculated) 1.221 Mg/m
3 
Wavelength 0.71073 Å 
Temperature 100(2) K 
F(000) 1736 
Absorption coefficient 0.084 mm
-1 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.990 and 0.964 
Theta range for data collection 1.554 to 28.344
o
 
Reflections collected 40661 
Independent reflections 10800 [R(int) = 0.0586] 
Data / restraints / parameters 10800 / 118 / 573 
wR(F
2
 all data) wR2 = 0.1925 




Observed data [I>2σ(I)] 9029 
Absolute structure parameter 1.2(6) 
Largest and mean shift / s.u. 0.012 and 0.000 
Largest diff. peak and hole 0.315 and -0.374 
 












R1 = Σ ||Fo| - |Fc|| / Σ |Fo|  
96 
Table A4. Atomic coordinates and equivalent isotropic displacement parameters for 9. 









Table A5. Bond lengths [Å] and angles [
o





















) for 9. The anisotropic 


























Table 8. Torsion angles [
o




















Figure A1. Screenshot of antiSMASH results for secondary metabolite gene cluster 15; 
the cluster predicted to produce glidobactin-like compounds. KS = ketosynthase, A = 
AMP binding domain, C = condensation domain, AT = acyltransferase, KR = 











































































































































































































































































































































































Figure A9. In vitro cytoxicity (upper panel) and protesome inhibition (lower panel) for 










































































































































































































C gHMBC (500 MHz, DMSOd6, 25
o
C) of 8. Spectrum zoomed in to 



























































































































































































































































H tCOSY (500 MHz, DMSOd6, 25
o
C) spectrum of compound 9. 
Colored lines indicate spin system originating from NH groups (far left and bottom) and 













H gCOSY (500 MHz, DMSOd6, 25
o








H NOESY (500 MHz, DMSOd6, 25
o















N HSQC (500 MHz, DMSOd6, 25
o
C) of compound 9. Figure shows 
overlay of two NMR experiments. The first experiment was run to show on NH signales 
(in red). The second showed NH and NH2. Both experiments overlayed exactly, 
















Figure A24. Chromatograms of standard D and L-amino acids. PDA trace (top panel) 
and MS single ion trace (bottom panel) of amino acids. Mass trace shows that although 
they overlap in the PDA chromatogram, S-phenylalanine and and L-leucine can be 
resolved by looking at the ion trace specific for each molecules m/z.  
136 
 
Figure A25. Marfey’s analysis of 9. PDA trace (top panel) and single ion trace (bottom 
panel). The Marfey’s analysis confirmed the presence of S-phenylalanine. Which lead 
to the final assignment of all L-prolines. D and L leucine exists in a roughly 1:2 ratio, 
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